ENGN · enGene Therapeutics Inc
United States · RS rating 7 · As of 2026-10-14
| Price | 1.56 USD |
|---|---|
| 1-day change | -4.3% |
| RS rating (overall / 1M / 3M / 12M) | 7 / 13 / 20 / 6 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 15 / 3 / 23 |
| Industry group (rank) | Medical-Generic Drugs (94) |
| EPS growth Q/Q | +2.3% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +87.2% |
| Market cap (USD) | $545.3M |